Orchestra BioMed Holdings (OBIO) Cash from Investing Activities Growth (1y) (2023 - 2026)

Orchestra BioMed Holdings (OBIO) Cash from Investing Activities Growth (1y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Investing Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 90.55%
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 91.53%
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 25.90%
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 7,936.68%
7 Royalty Pharma 33.72 Bn 35.84 Bn - 26.37%
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -157.08%
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -89.24%
10 Orchestra BioMed Holdings 265.06 Mn 80.63 Mn 63,000.00 -242.51%

Historic Data

Download Data
DateValue
Jun 30, 2026 -242.51%
Mar 31, 2026 -20.62%
Dec 31, 2025 -371.94%
Sep 30, 2025 -7,027.11%
Jun 30, 2025 56.91%
Mar 31, 2025 121.79%
Dec 31, 2024 -111.32%
Sep 30, 2024 -95.70%
Jun 30, 2024 28.41%
Mar 31, 2024 113.46%
Dec 31, 2023 152.31%
Sep 30, 2023 5,879.91%
Jun 30, 2023 1,812.66%
Mar 31, 2023 -92,514.89%